Apixaban increases bleeding with no benefit in high-risk patients with ACS

Apixaban increases bleeding with no benefit in high-risk patients with ACS is a topic covered in the EE+ POEM Archive.

To view the entire topic, please log in or purchase a subscription.

Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Explore these free sample topics:

20 mcg versus >20 mcg estrogen combined oral contraceptives for contraception

"Snowball fingers" - Image

Botulinum toxin for the treatment of strabismus: Cochrane systematic review

ACC/AHA: Fewer patients require prophylaxis for endocarditis

There's more to see -- the rest of this topic is available only to subscribers.